Sells neffy, a needle-free epinephrine nasal spray for emergency treatment of severe allergic reactions, to pharmaceutical wholesalers and pharmacy customers, for use by patients and healthcare providers.
10-K for FY2025, filed Mar 9, 2026
U.S. customers buy neffy through wholesale distributors and pharmacies; the company is paid when products are delivered, or when a pharmacy sells a consigned product to a patient. Collaboration partners pay for licenses, milestones and royalties, and can also buy product supply.
10-K for FY2025, filed Mar 9, 2026The Company’s product, neffy, was approved by the FDA in August 2024, and the Company began generating product revenue from sales of neffy…View ↗
The Company uses a third-party logistics provider to support the warehousing, distribution, order processing, accounts receivable, and data…View ↗
The Company also enters into consignment agreements with certain pharmacies, under which revenue is recognized when the product is sold to…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license…View ↗
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗$84.3M
10-K for FY2025, filed Mar 9, 2026
$84.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
86% |
Product revenue, net, FY2025
$72.2M Sources
|
Sold outright |
|
Revenue under collaboration agreements
|
12% |
Revenue under collaboration agreements, FY2025
$9.7M Sources
|
|
|
Revenue under supply agreements
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
2.8% |
Revenue under supply agreements, FY2025
$2.4M Sources
|
Sold outright |
In the U.S., the company sells mainly to pharmaceutical wholesale distributors, with some sales to pharmacy customers; they resell to pharmacies and healthcare providers or dispense directly to patients. Outside the U.S., licensing and distribution partners commercialize neffy in their territories.
10-K for FY2025, filed Mar 9, 2026We have established robust marketing, sales, and distribution capabilities to support the launch of neffy in the U.S. through an…View ↗
The Company’s product, neffy, was approved by the FDA in August 2024, and the Company began generating product revenue from sales of neffy…View ↗
The Company uses a third-party logistics provider to support the warehousing, distribution, order processing, accounts receivable, and data…View ↗
We have funded our operations to date primarily with proceeds from our equity financing from a syndicate of leading life sciences investors…View ↗
No. It lost $171.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$35.6MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 13, 2026
Targeted commercial execution. ARS Pharma is shifting its focus from broad consumer-directed marketing to targeted engagement with…View ↗
8-K, filed Jul 7, 2026
On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current…View ↗
Growing. Revenue grew 15.3x in 4 years, from $5.5M in FY2021 to $84.3M in FY2025, about 98% a year.
From development to commercialization
The older report described neffy as an investigational product candidate in clinical trials. The latest report describes neffy as an approved product that the company is commercializing, alongside ongoing development.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 9, 2026We are a biopharmaceutical company focused on the development of our novel, potentially first-in-class product candidate, neffy®…View ↗
U.S. sales through wholesalers
The latest report describes U.S. sales to pharmaceutical wholesale distributors and pharmacy customers, which then supply pharmacies, healthcare providers, or patients. The older report focused on developing neffy and prospective commercialization.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 9, 2026We are a biopharmaceutical company focused on the development of our novel, potentially first-in-class product candidate, neffy®…View ↗
Competes with Viatris, Teva Pharmaceuticals, Amneal Pharmaceuticals, Kaleo, Sandoz, Bryn Pharma, Hikma Pharmaceuticals, Nasus Pharma, Orexo, Insignis Therapeutics, Belhaven BioPharma, and Aquestive Therapeutics
10-K for FY2025, filed Mar 9, 2026neffy competes primarily against epinephrine intra-muscular injectable products, for the emergency treatment of Type I allergic reactions…View ↗
Loading...